Hjem › Blærekreft › Michigan › Detroit
Kliniske studier for Blærekreft i Detroit, MI
11 studier for Blærekreft søker deltakere på steder i og rundt Detroit (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
RekruttererFase 2
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RekruttererFase 3
- Karmanos Cancer Institute, Detroit
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RekruttererFase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
RekruttererFase 3
- Henry Ford Hospital, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
RekruttererFase 1/2
- Henry Ford Health System, Detroit
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
RekruttererFase 2/3
- Karmanos Cancer Institute, Detroit
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
RekruttererFase 2
- Karmanos Cancer Institute, Detroit
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
A Beta-only IL-2 ImmunoTherapY Study
RekruttererFase 1/2
- Karmanos Cancer Institute, Detroit
Blærekreft-studier i andre byer
- New York City, NY35 studier
- Nashville, TN31 studier
- Houston, TX31 studier
- Dallas, TX27 studier
- Washington, DC26 studier
- Boston, MA26 studier
- Baltimore, MD24 studier
- Los Angeles, CA24 studier
- St. Louis, MO22 studier
- Seattle, WA21 studier
- Chicago, IL21 studier
- Philadelphia, PA21 studier
Andre studier i Detroit
- Ikke-småcellet lungekreft44 studier
- Brystkreft33 studier
- Kreft (alle typer)29 studier
- Kolorektal kreft26 studier
- Eggstokkreft26 studier
- Metastatisk kreft24 studier
- Prostatakreft22 studier
- Endometriekreft21 studier
- Lungekreft20 studier
- Multipelt myelom19 studier
- Mavekreft16 studier
- Plateepitelcancer i hode og hals15 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.